{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:37:37Z","timestamp":1777480657900,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CBM"],"published-print":{"date-parts":[[2022,9,19]]},"abstract":"<jats:p>BACKGROUND: Combination of different cancer markers is often used for predicting tumor growth, for the response to cancer therapy, and for increase in the positive diagnosis ratio in the malignant tumors. OBJECTIVE: Evaluation of the diagnostic efficacy of CA 15-3 and CA-62 cancer markers combination for early stages of breast cancer (BC) detection. METHODS: This blind study was performed on 2 clinically validated Sets that included serum measurements of CA 15-3 ELISA and CLIA-CA-62 assays in 488 serum samples with TNM classification. A study included 300 BC patients (254 at Stages I and II, 20 with ductal carcinoma in situ (DCIS), and 26 Stages III and IV patients), 47 patients with breast benign diseases, and 141 healthy controls. RESULTS: Sensitivity for DCIS &amp; Stage I breast cancer detection was 75% at 100% Specificity (AUC = 0.895) using a following combination of two antigens: 10 &lt; CA15-3 &lt; 46 U\/ml and CA-62 \u2a7e 6300 U\/ml, which allows eliminating false positive results. CONCLUSIONS: The results obtained in a blind study demonstrate that a combination of CA15-3 with CA-62 yields 75% Sensitivity at 100% Specificity for DCIS and Stage I breast cancer detection, which has a potential to be integrated into existing screening programs.<\/jats:p>","DOI":"10.3233\/cbm-210533","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T04:58:16Z","timestamp":1656478696000},"page":"57-69","source":"Crossref","is-referenced-by-count":7,"title":["Diagnostic efficacy of the new prospective biomarker\u2019s combination CA 15-3 and CA-62 for early-stage breast cancer detection: Results of the blind prospective-retrospective clinical study"],"prefix":"10.1177","volume":"35","author":[{"given":"Janneta","family":"Tcherkassova","sequence":"first","affiliation":[{"name":"JVS Diagnostics LLC, Skolkovo IC, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Prostyakova","sequence":"additional","affiliation":[{"name":"Shemaykin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey","family":"Tsurkan","sequence":"additional","affiliation":[{"name":"JVS Diagnostics LLC, Skolkovo IC, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladislav","family":"Ragoulin","sequence":"additional","affiliation":[{"name":"JVS Diagnostics LLC, Skolkovo IC, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Boroda","sequence":"additional","affiliation":[{"name":"World-Class Research Center \u201cDigital Biodesign and Personalized Healthcare\u201d, Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Sekacheva","sequence":"additional","affiliation":[{"name":"World-Class Research Center \u201cDigital Biodesign and Personalized Healthcare\u201d, Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"14","key":"10.3233\/CBM-210533_ref1","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/0959-8049(94)00356-A","article-title":"Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease","volume":"20","author":"Berruti","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.3233\/CBM-210533_ref2","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/pharmaceutics13050723","article-title":"Current state of breast cancer diagnosis, treatment, and theranostics","volume":"13","author":"Bhushan","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.3233\/CBM-210533_ref3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/bjc.2016.433","article-title":"Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples","volume":"116","author":"Kazarian","year":"2017","journal-title":"Br J Cancer"},{"issue":"4","key":"10.3233\/CBM-210533_ref4","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1148\/rg.234025083","article-title":"Missed breast carcinoma: Pitfalls and pearls","volume":"23","author":"Majid","year":"2003","journal-title":"RadioGraphics"},{"key":"10.3233\/CBM-210533_ref6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/annonc\/mdm538","article-title":"Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes","volume":"19","author":"Park","year":"2008","journal-title":"Ann Oncol of Eur Soc Med Oncol (ESMO)"},{"issue":"9","key":"10.3233\/CBM-210533_ref7","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","article-title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","volume":"32","author":"Klein","year":"2021","journal-title":"Annals Oncology"},{"issue":"22","key":"10.3233\/CBM-210533_ref8","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.2014.56.1514","article-title":"Rethinking breast cancer screening: Ultra FAST breast magnetic resonance imaging","volume":"32","author":"Morris","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.3233\/CBM-210533_ref9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2020","journal-title":"Cancer J Clin"},{"key":"10.3233\/CBM-210533_ref10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0166-0934(88)90099-7","article-title":"Use of heat inactivated viral haemorrhagic fever antigens in serological assays","volume":"22","author":"Saluzzo","year":"1988","journal-title":"J Virol Meth"},{"issue":"4","key":"10.3233\/CBM-210533_ref12","first-page":"213","article-title":"Evaluation of CA 15-3 tumor marker in the diagnosis of breast cancer. A pilot study","volume":"41","author":"Wojtacki","year":"1994","journal-title":"Neoplasma"},{"key":"10.3233\/CBM-210533_ref13","doi-asserted-by":"crossref","first-page":"e64366","DOI":"10.1371\/journal.pone.0064366","article-title":"If you don\u2019t find it often, you often don\u2019t find it: Why some cancers are missed in breast cancer screening","volume":"8","author":"Evans","year":"2013","journal-title":"PLoS One"},{"issue":"13","key":"10.3233\/CBM-210533_ref15","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2217\/bmm-2019-0085","article-title":"Detection of early breast cancer beyond mammographic screening: A promising biomarker panel","volume":"13","author":"Hamann","year":"2019","journal-title":"Biomark Med"},{"key":"10.3233\/CBM-210533_ref16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1373\/clinchem.2005.059832","article-title":"Serum tumor markers in breast cancer: Arethey of clinical value","volume":"52","author":"Duffy","year":"2006","journal-title":"Clin Chem"},{"key":"10.3233\/CBM-210533_ref17","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/J.CCA.2010.08.039","article-title":"CA 15-3: Uses and limitation as a biomarker for breast cancer","volume":"411","author":"Duffy","year":"2010","journal-title":"Clinica Chimica Acta"},{"key":"10.3233\/CBM-210533_ref18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/172460080001500410","article-title":"CA 15-3: A prognostic marker in breast cancer","volume":"15","author":"Duffy","year":"2000","journal-title":"Int J Biol Mark"},{"issue":"1","key":"10.3233\/CBM-210533_ref19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1021\/pr800545q","article-title":"Standard operating procedures for serum and plasma collection: Early detection research network consensus statement standard operating procedure integration working group","volume":"8","author":"Tuck","year":"2009","journal-title":"J Proteome Res"},{"issue":"7","key":"10.3233\/CBM-210533_ref20","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.31557\/APJCP.2019.20.7.2015","article-title":"Global trend of breast cancer mortality rate: A 25-year study","volume":"20","author":"Azamjah","year":"2019","journal-title":"Asia Pac J Cancer Prev"},{"issue":"11","key":"10.3233\/CBM-210533_ref21","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1001\/jamaoncol.2017.1256","article-title":"Breast cancer screening with mammography plus ultrasonography or magnetic resonance imaging in women 50 years or younger at diagnosis and treated with breast conservation therapy","volume":"3","author":"Cho","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.3233\/CBM-210533_ref22","unstructured":"N. Mittmann, N.K. Stout, P. Lee et al., Total cost-effectiveness of mammography screening strategies, Health Rep 26(12) (2015), 16-25.7."},{"key":"10.3233\/CBM-210533_ref23","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.181.3.1810687"},{"key":"10.3233\/CBM-210533_ref24","doi-asserted-by":"publisher","first-page":"e1226","DOI":"10.1259\/bjr\/15168178","article-title":"Improvement in sensitivity of screening mammography with computer-aided detection: A multiinstitutional trial","volume":"85","author":"Hofvind","year":"2012","journal-title":"The British Journal of Radiology"},{"issue":"17","key":"10.3233\/CBM-210533_ref25","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.18632\/oncotarget.2370","article-title":"Altered Mucins (MUC) trafficking in benign and malignant conditions","volume":"5","author":"Joshi","year":"2014","journal-title":"Oncotarget"},{"key":"10.3233\/CBM-210533_ref26","doi-asserted-by":"publisher","first-page":"100985","DOI":"10.1016\/j.eclinm.2021.100985","article-title":"Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns","volume":"38","author":"Lima","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.3233\/CBM-210533_ref27","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1038\/bjc.2015.49","article-title":"Stage at diagnosis and early mortality from cancer in England","volume":"112","author":"McPhail","year":"2015","journal-title":"Br J Cancer"},{"key":"10.3233\/CBM-210533_ref28","doi-asserted-by":"publisher","first-page":"5529106","DOI":"10.1155\/2021\/5529106","article-title":"Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer","volume":"2021","author":"Zhao","year":"2021","journal-title":"Dis Markers"},{"issue":"2","key":"10.3233\/CBM-210533_ref29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1148\/radiol.2016151174","article-title":"Risk of Breast Cancer in Women with False-Positive Results according to Mammographic Features","volume":"280","author":"Castells","year":"2016","journal-title":"Radiology"},{"issue":"2","key":"10.3233\/CBM-210533_ref30","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3892\/etm.2020.8868","article-title":"Clinical value of color Doppler ultrasound combined with serum CA153, CEA and TSGF detection in the diagnosis of breast cancer","volume":"20","author":"Song","year":"2020","journal-title":"Experimental and Therapeutic Medicine"}],"container-title":["Cancer Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/CBM-210533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:08:47Z","timestamp":1777385327000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/CBM-210533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":27,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/cbm-210533","relation":{},"ISSN":["1875-8592","1574-0153"],"issn-type":[{"value":"1875-8592","type":"electronic"},{"value":"1574-0153","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,19]]}}}